Updated insights into the impact of adjuvant chemotherapy on recurrence and survival after curative resection of liver or lung metastases in colorectal cancer: a rapid review and meta-analysis

Table 1 Characteristics of included studies

Study	Year	Country	Study design	Metastasis site	Patients	Comparative outcomes	Follow-up	Age	Sex	Location of the primary colorectal cancer	Timing of metastasis	Preoperative chemotherapy	AC regimen
Kobayashi	2020	Japan	Retrospective	Liver	AC n = 211, SA n = 211	OS, RFS	79.4 months	AC 63.5 years, SA 65.4 years	Male 268, Female 154	Colon 316, Rectum 106	Synchronous 244 Metachronous 278	No	FOLFOX, FOLFIRI
Kanemitsu	2021	Japan	RCT	Liver	AC n = 151, SA n = 149	OS, DFS	53.6 months	AC 65 years, SA 63 years	Male 180, Female 120	Colon 232, Rectum 68	Synchronous 167 Metachronous 133	No	mFOLFOX6
Kokudo	2021	Japan	RCT	Liver	AC n = 88, SA n = 89	OS, RFS	88.3 months	AC 62.3 years, SA 64.4 years	Male 120, Female 57	Colon 110, Rectum 67	Synchronous 79 Metachronous 98	No	UFT/LV
Kelm	2021	Germany	Retrospective	Liver	AC n = 34, SA m = 41	OS, DFS	NR	AC 65 years, SA 65 years	Male 48, Female 27	Colon 44, Rectum 31	Metachronous 75	Yes: 13, No: 62	FOLFOX, FOLFIRI, CAPOX, Capecitabine (n = 10)
Boerner	2021	USA	Retrospective	Liver	AC n = 77, SA n = 83	OS, RFS	96 months	AC 59.2 years, SA 67.9 years	Male 87, Female 73	Colon 122, Rectum 38	Metachronous 160	Yes: 21, No: 139	Oxaliplatin or Irinotecan
Imanishi	2019	Japan	Retrospective	Lung	AC m = 192, SA n = 192	OS, DFS	54 months	AC 65 years, SA 67 years	Male 212, Female 172	Colon 158, Rectum 226	Synchronous 45 Metachronous 339	No	Fluoropyrimidine (n = 136), Oxaliplatin-based, Irinotecan-based
Hansdotter	2023	Sweden	Retrospective	Lung	AC n = 29, SA n = 33	OS	NR	NR	NR	NR	NR	No	NR

AC, adjuvant chemotherapy; SA, surgery alone; RCT, randomized controlled trial; NR, not reported; USA, united states of America

ISSN: 1477-7819